PCPaolo Vittoriano Clini

Paolo Vittoriano Clini

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Paolo Vittoriano Clini has a total of 16 co-authors. Here are the top co-authors by number of shared publications:

  • Elvis Hysa

    Laboratory of Experimental Rheumatology and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, Genoa, Italy

    3 shared publications
  • Alberto Sulli

    Laboratory of Experimental Rheumatology and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genoa

    2 shared publications
  • Emanuele Gotelli

    Laboratory of Experimental Rheumatology, Division of Rheumatology, Department of Internal Medicine and Medical Specialties (Di.M.I.), University of Genova, 16132 Genova, Italy

    2 shared publications
  • Maurizio Cutolo

    Laboratory of Experimental Rheumatology and Academic Division of Clinical Rheumatology, Department of Internal Medicine (DiMI) University of Genova Genoa Italy

    2 shared publications
  • Sabrina Paolino

    Laboratory of Experimental Rheumatology, Division of Rheumatology, Department of Internal Medicine and Medical Specialties (Di.M.I.), University of Genova, 16132 Genova, Italy

    2 shared publications
  • Vanessa Smith

    Department of Rheumatology, Ghent University Hospital, Ghent, Belgium

    2 shared publications

Latest Publications

  • Open Access

    An engineered glove to follow finger function in rheumatoid arthritis: an observational prospective study

    by A. Sulli, P. Clini, G. Bruzzone, A. Signori, T. Vojinovic, S. Paolino, E. Gotelli, E. Hysa, V. Smith, M. Cutolo

    The engineered Hand Test System (HTS) glove has shown high reliability in assessing the baseline functional status of rheumatoid arthritis (RA) hand. Starting from this achievement, the aim of the present observational prospective study was to assess the functionality of the single fingers of rheumatoid hand at follow-up. Eighty RA patients performed HTS glove tests at baseline and among these fifty-six patients were re-tested after 7 months. The HTS glove parameters [Touch Duration (TD), Movement Rate (MR), Inter Tapping Interval (ITI)] were correlated with disease activity and disability clinimetric indexes [Disease Activity Score 28 joint count—C-reactive protein (DAS28-CRP), Clinical Disease Activity Index (CDAI), Simplified Disease Activity Index (SDAI), Health Assessment Questionnaire—Disability Index (HAQ-DI), grip strength, visual analogue scale of pain (VAS), patient global assessment (PGA)], and with laboratory values. HTS glove parameters (TD, ITI, and MR) showed statistically significant correlations with clinimetric and clinical indexes at both time points (p < 0.05). During follow-up, a statistically significant variation of all HTS glove parameters for the fingers that have performed both the worst or best HTS test at baseline was detected (p < 0.05), while the mean HTS glove parameter values by considering all fingers did not show a statistically significant variation over time, as well as the traditional clinimetric indexes. Besides the objective role in assessing the RA hand function by integrating the traditional clinimetric indexes, the HTS glove seems a useful tool for evaluating worst or best finger function during time by measuring the movement speed.


  • Open Access

    AB0734 POLYPHARMACY AND COMORBIDITIES ARE NOT INCREASED AT DIAGNOSIS IN PATIENTS WITH POLYMYALGIA RHEUMATICA

    by M. A. Cimmino, E. Hysa, P. Clini, D. Camellino

    Background Polypharmacy, the prescription of multiple drugs for an individual patient, is increasing especially in ageing individuals with comorbidities. Polymyalgia rheumatica (PMR) is an inflammatory disease of the elderly causing pain and stiffness in the girdles. A recent systematic review showed that cardiovascular disease and lymphoproliferative disorders could be possibly increased in PMR patients, but the quality of the included studies was relatively poor. In addition, some comorbidities could be caused by PMR treatment and not by the disease itself. Objectives Our study is concerned with an evaluation of polypharmacy and comorbidities in PMR patients at diagnosis. Methods Patients were enrolled if they fulfilled the 2012 EULAR/ACR provisional criteria for PMR. Sex and age-matched controls were patients with hand OA diagnosed according to the 1990 ACR clinical criteria and seen in the same private outpatient clinic as patients. Both groups were interviewed at the time of diagnosis for the type and number of assumed drugs and comorbidities by the same investigator. The rheumatic diseases comorbidity index (RCDI) was used. Results 83 PMR patients (median 75 years, range 50-88 years, 65.1% women) and 83 controls (median 72 years, range 53-90 years, 65.1% women) were studied. Median disease duration was 2 months (0.3-8 months) and median glucocorticoid dose before assessment was 0 mg (0-750 mg). The mean number of drugs assumed by PMR patients was 2.5±2.1 in comparison with 3.0±2.2 of controls (p=0.129). PMR patients with hip pain assumed less drugs (2.1±1.8 vs. 3.7±2.3, p=0.008) and those with morning stiffness >45 minutes assumed more drugs (2.8±2.1 vs. 2.8±2.1, p=0.001). The mean RDCI was 1.58±1.29 in PMR patients and 1.45±1.36 in controls (p=0.52). The frequency of the individual comorbidities in PMR patients and controls is reported in Table 1. No difference was observed in cancer type. Number of assumed drugs and RDCI significantly correlated (r=0.58; pConclusion When considered at the time of diagnosis, PMR patients do not show an increased comorbidity index nor number of assumed drugs in comparison with OA controls. Only gastric disease was lower, possibly due to the increased NSAIDs use in OA patients. Frequency of the individual comorbidities in PMR patients and controls (Co). REFERENCES: NIL. Acknowledgements: NIL. Disclosure of Interests None Declared.

  • Open Access

    Metabolic Profile and Bone Status in Post-Menopausal Women with Rheumatoid Arthritis: A Monocentric Retrospective Survey

    by Sabrina Paolino, Elvis Hysa, Sabrina Atena Stoian, Emanuele Gotelli, Andrea Casabella, Paolo Vittoriano Clini, Greta Pacini, Carmen Pizzorni, Alberto Sulli, Elena Nikiphorou, et al.

    Background: Rheumatoid arthritis (RA) and metabolic syndrome (MetS) are chronic conditions that share common inflammatory mechanisms. Both diseases can lead to an impairment of the bone microarchitecture. The aims of our study were to evaluate clinical, metabolic, and bone parameters in RA patients with or without MetS (MetS+, MetS−) and potential correlations between the glico-lipidic profile, RA disease activity, and bone status. Methods: A total of thirty-nine RA female post-menopausal patients were recruited (median age 66.6 ± 10.4, disease duration 3 ± 2.7). Anthropometric data, medical history, and current treatment were recorded along with basal blood tests, bone, and lipid metabolism biomarkers. RA disease activity and insulin resistance were evaluated through standard scores. Quantitative assessment of the bone (bone mineral density—BMD) was performed by dual-energy-X ray absorption (DXA), whereas bone quality was quantified with the trabecular bone score (TBS). Results: No statistically significant differences concerning both BMD and TBS were detected between the MetS+ and MetS− RA patients. However, the MetS+ RA patients exhibited significantly higher disease activity and lower serum 25-hydroxyvitamin D [25(OH)D] concentrations (respectively, p = 0.04 and p = 0.01). In all RA patients, a significant negative correlation emerged between the BMD of the femoral trochanter with plasmatic triglycerides (TG) concentrations (r = −0.38, p = 0.01), whereas the lumbar BMD was positively correlated with the abdominal waist (AW) and fasting glucose (FG) concentrations. On the other hand, the TBS was negatively correlated with insulin concentrations, FG, and RA disease activity (respectively, r = −0.45, p = 0.01, r = −0.40, p = 0.03, r = −0.37, p = 0.04), the last one was further negatively correlated with 25-OHD serum concentrations (r = −0.6, p = 0.0006) and insulin-resistance (r = 0.3, p = 0.04). Conclusions: Bone quantity (BMD) and quality (TBS) do not seem significantly changed among MetS+ and MetS− RA patients; however, among MetS+ patients, both significantly higher disease activity and lower vitamin D serum concentrations were observed. In addition, the significant negative correlations between the alterations of metabolic parameters limited to the TBS in all RA patients might suggest that qualitative bone microarchitecture impairments (TBS) might manifest despite unchanged BMD values.